Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.75 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840588 | 1.00 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11NPSR1 | |
| SCHEMBL4839139 | 0.95 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4839149 | 0.95 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4832134 | 0.92 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11MEN1 | |
| SCHEMBL4832129 | 0.92 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11MEN1 | |
| SCHEMBL4838179 | 0.91 | MAPK14 (0.76) | MAPK14MEN1MAPTKMT2A | |
| SCHEMBL4838192 | 0.91 | MAPK14 (0.76) | MAPK14MEN1MAPTKMT2A | |
| SCHEMBL4836040 | 0.89 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL4836030 | 0.89 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL4836866 | 0.89 | MAPK14 (0.75) | MAPK14NPSR1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402589-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-07-22 | — | — | US | claimed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | claimed |
| US-7402589-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-07-22 | — | — | US | disclosed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | MAPK14 2674/4885MAPK13 2480/4885MAPK12 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.